Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1123548 | 0.73 | SRC (0.47) | ALDH1A1MEN1KMT2AKDM4EHTT | |
| SCHEMBL6889234 | 0.71 | SRC (0.42) | KDM4EMAPTL3MBTL1TDP1 | |
| SCHEMBL13327132 | 0.70 | SMN1; SMN2 (0.44) | ALDH1A1SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL11676453 | 0.70 | HPGD (0.65) | ALDH1A1SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL19341895 | 0.70 | SRC (0.47) | ALDH1A1SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL19341896 | 0.70 | ALOX12 (0.46) | ALDH1A1SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL16182028 | 0.69 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL9782104 | 0.68 | SRC (0.48) | TSHRMEN1KMT2AKDM4EMAPT | |
| SCHEMBL13583550 | 0.68 | PARL (0.57) | ALDH1A1SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL2858596 | 0.68 | SRC (0.52) | TSHRMEN1KMT2AKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2023-10-19 | — | — | US | disclosed |
| EP-4200309-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | ATEA Pharmaceuticals, Inc. (US) | 2023-06-28 | — | — | EP | disclosed |
| EP-3980057-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | Institut Curie (FR) | 2022-04-13 | — | — | EP | disclosed |
| WO-2022040473-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2022-02-24 | — | — | WO | disclosed |
| US-10959987-B2 | Imidazole-based compounds as hepatitis C virus inhibitors | KING ABDULAZIZ UNIVERSITY (SA) | 2021-03-30 | — | — | US | disclosed |
| WO-2020245321-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2020-12-10 | — | — | WO | disclosed |
| US-20200368204-A1 | COMPOUNDS FOR INHIBITING NS3 AND COMPOSITIONS CONTAINING THE INHIBITED PROTEIN | KING ABDULAZIZ UNIVERSITY (SA) | 2020-11-26 | — | — | US | disclosed |
| US-10821096-B1 | Compounds for inhibiting NS3 and compositions containing the inhibited protein | KING ABDULAZIZ UNIVERSITY (SA) | 2020-11-03 | — | — | US | disclosed |
| US-20200323822-A1 | IMIDAZOLE-BASED COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | KING ABDULAZIZ UNIVERSITY (SA) | 2020-10-15 | — | — | US | disclosed |
| EP-2340271-B1 | POLYMER-BIOACTIVE AGENT CONJUGATES | POLYACTIVA PTY LTD (AU) | 2018-12-05 | — | — | EP | disclosed |
| EP-3134381-A1 | TERPENE AND TERPENOID DERIVATIVES CONTAINING VINYL GROUPS FOR THE PREPARATION OF POLYMERS | The University of Nottingham (GB) | 2017-03-01 | — | — | EP | disclosed |
| US-20170044282-A1 | TERPENE AND TERPENOID DERIVATIVES CONTAINING VINYL GROUPS FOR THE PREPARATION OF POLYMERS | THE UNIVERSITY OF NOTTINGHAM (GB) | 2017-02-16 | — | — | US | disclosed |
| WO-2015162419-A1 | TERPENE AND TERPENOID DERIVATIVES CONTAINING VINYL GROUPS FOR THE PREPARATION OF POLYMERS | THE UNIVERSITY OF NOTTINGHAM (GB) | 2015-10-29 | — | — | WO | disclosed |
| US-20150183818-A1 | PROCESS FOR PREPARING DIASTEREOMERICALLY ENRICHED PHOSPHORAMIDATE DERIVATIVES OF NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-02 | — | — | US | disclosed |
| EP-2870169-A1 | PROCESS FOR PREPARING DIASTEREOMERICALLY ENRICHED PHOSPHORAMIDATE DERIVATIVES OF NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | Bristol-Myers Squibb Company (US) | 2015-05-13 | — | — | EP | disclosed |
| WO-2014008236-A1 | PROCESS FOR PREPARING DIASTEREOMERICALLY ENRICHED PHOSPHORAMIDATE DERIVATIVES OF NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-09 | — | — | WO | disclosed |
| WO-2001000609-A9 | METHOD FOR SYNTHESIS OF N-HOMOCYSTEINE THIOLACTONYL RETINAMIDE | UNIV BAYLOR (US) | 2002-07-25 | — | — | WO | disclosed |
| US-6287818-B1 | CONJUGATING, IN SINGLE REACTION MIXTURE, RETINOIC ACID WITH HOMOCYSTEINE THIOLACTONE TO FORM N-HOMOCYSTEINE THIOLACTONYL RETINAMIDE, THEN MIXING WITH 5'-DEOXYADENOSINE COBALAMIN; HIGH PURITY AND YIELD; ANTICANCER AGENTS WITH REDUCED TOXICITY | BAYLOR UNIVERSITY | 2001-09-11 | — | — | US | disclosed |
| WO-2001000609-A1 | METHOD FOR SYNTHESIS OF N-HOMOCYSTEINE THIOLACTONYL RETINAMIDE | BAYLOR UNIVERSITY (US) | 2001-01-04 | — | — | WO | disclosed |
| US-6054595-A | REACTING RETINOIC ACID WITH HOMOCYSTEINE THIOLACTONE | BAYLOR UNIVERSITY (US) | 2000-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200368204-A1 | COMPOUNDS FOR INHIBITING NS3 AND COMPOSITIONS CONTAINING THE INHIBITED PROTEIN | MAVS, CUL1, CUL3 | ALDH1A1 3525/4885SMN1; SMN2 4468/4885TSHR 4719/4885 |
| US-20200323822-A1 | IMIDAZOLE-BASED COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | HAVCR2, MAVS, ZC3HAV1 | ALDH1A1 1548/4885SMN1; SMN2 4742/4885TSHR 4071/4885 |
| US-20150183818-A1 | PROCESS FOR PREPARING DIASTEREOMERICALLY ENRICHED PHOSPHORAMIDATE DERIVATIVES OF NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | SAMHD1, TYMP, PNP | ALDH1A1 1868/4885SMN1; SMN2 433/4885TSHR 4237/4885 |
| US-10821096-B1 | Compounds for inhibiting NS3 and compositions containing the inhibited protein | MAVS, CUL1, CUL3 | ALDH1A1 3525/4885SMN1; SMN2 4468/4885TSHR 4719/4885 |
| US-20170044282-A1 | TERPENE AND TERPENOID DERIVATIVES CONTAINING VINYL GROUPS FOR THE PREPARATION OF POLYMERS | GGPS1, DHPS, FDPS | ALDH1A1 966/4885SMN1; SMN2 4751/4885TSHR 4694/4885 |
| US-10959987-B2 | Imidazole-based compounds as hepatitis C virus inhibitors | HAVCR2, MAVS, ZC3HAV1 | ALDH1A1 1548/4885SMN1; SMN2 4742/4885TSHR 4071/4885 |
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | NUDT1, PNP, ATIC | ALDH1A1 946/4885SMN1; SMN2 1243/4885TSHR 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.